We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Tumors Grow When Normal Cells Are Induced to Become Cancerous

By LabMedica International staff writers
Posted on 13 Dec 2015
Print article
Image: Ribbon representation of a repeating unit in the extracellular E-cadherin ectodomain (Photo courtesy of Wikimedia Commons).
Image: Ribbon representation of a repeating unit in the extracellular E-cadherin ectodomain (Photo courtesy of Wikimedia Commons).
A recent study determined how the cancer cells within a tumor promote its growth by transforming neighboring normal epithelial cells into cancer cells.

In epithelial cancers, carcinoma cells coexist with normal cells. Although it was known that the tumor microenvironment played a pivotal role in cancer progression, it was not completely understood how the tumor influenced adjacent normal epithelial cells.

In a recent study, investigators at the University of Delaware (Newark, USA) employed a three-dimensional co-culture system comprising non-transformed epithelial cells (MDCK) and transformed carcinoma cells (MSV-MDCK) to demonstrate that carcinoma cells sequentially induced cancer-like changes, including preneoplastic lumen filling and epithelial–mesenchymal transition (EMT) in epithelial cysts.

The investigators found that at the molecular level, the protease MMP-9 (matrix metallopeptidase 9) secreted by carcinoma cells cleaved cellular E-cadherin from epithelial cells to generate soluble E-cadherin (sE-cad), a pro-oncogenic protein.

Cadherins are members of a family of calcium-dependent cell adhesion proteins that preferentially interact in a homophilic manner in cell-cell interactions. They are type I membrane proteins that contribute to the sorting of heterogeneous cell types. Typically, cadherins have five similar extracellular domains, the outermost three of which have Ca2+-binding sites, and an intracellular C-terminal domain that interacts with the actin cytoskeleton. Loss of E-cadherin function or expression has been implicated in cancer progression and metastasis. E-cadherin downregulation decreases the strength of cellular adhesion within a tissue, resulting in an increase in cellular motility. This in turn may allow cancer cells to cross the basement membrane and invade surrounding tissues.

In the current study, the investigators showed that sE-cad induced EGFR (epidermal growth factor receptor) activation, resulting in lumen filling in MDCK cysts, and that long-term sE-cad treatment induced EMT. Therefore, they were able to demonstrate that carcinoma cells could induce sE-cad shedding in adjacent epithelial cells, which led to EGFR activation and the eventual transdifferentiation of the normal epithelial cells.

Senior author Dr. Ayyappan Rajasekaran, adjunct professor of materials science and engineering at the University of Delaware, said, "This is the first time research has demonstrated that a cancer cell can sequentially induce early and late stages of cancer development in neighboring normal cells—a fundamental finding that can inform future studies. Like bacteria and viruses, cancer cells have the potential to infect normal cells and promote cancer progression. Future studies should give a new dimension to our understanding of cancer development and treatment."

Related Links:

University of Delaware


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.